NCT01716923已完成3 期
A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S 303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 81
- 试验地点
- 2
- 主要终点
- Primary Efficacy Endpoint - mean hemoglobin content
研究概览
简要总结
The clinical study will assess the in-vitro characteristics of red blood cells (RBCs) per the European Union (EU) criteria for leukocyte depleted RBCs in additive solution and evaluate the safety and efficacy of S-303 treated RBCs in a patient population requiring RBC transfusion support for acute anemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years, of either gender.
- •Must be willing to use an acceptable form of contraceptive while on study (as approved by the Investigator or designee)
- •Must be readily available by telephone
- •Must provide an informed consent for study participation and have signed an ethics committee (EC)-approved informed consent
- •Must have a negative cross match to S 303 red blood cells (RBCs) at study entry
- •Must have a blood type of either A+ or O+
- •Patients must have a likelihood of receiving a transfusion as determined by the Investigator OR a Transfusion Risk Understanding Screening Tool (TRUST) Score of ≥3 at study entry
- •Must be scheduled to receive one of the following operative procedures:
- •Coronary artery bypass graft only, first procedure
- •Valve repair or replacement only, first procedure
- •A combination of first time Coronary Artery Bypass Graft (CABG) and valve repair or replacement
- •After consultation with the Medical Monitor, provision can be made to enroll patients who may meet these general criteria but whose surgical procedure is not precisely described in the above categories. Such patients will be classified as "other" with their explicit condition reported with other study data.
排除标准
- •A positive pregnancy test result
- •Inability of patient to comply with the protocol in the opinion of the Investigator or attending physician
- •Breast-feeding of an infant or child
- •Active autoimmune hemolytic anemia, or a positive Direct Antiglobulin Test (DAT) result
- •Treatment with any medication that is known to adversely affect red blood cell viability
- •Emergent or salvage surgical status at the time of surgery defined as follows:
- •Presence of ongoing ischemia including angina at rest despite maximal medical therapy
- •Acute evolving myocardial infarction within 24 hours before surgery
- •Pulmonary edema requiring intubation
- •Presence of shock or hemodynamic instability with or without circulatory support
- •Systolic blood pressure < 80 mm Hg and/or Cardiac Index < 1.8 despite medical intervention (intravenous inotropes or similar pharmacologic agents)
- •Cardiopulmonary resuscitation in the 24 hours prior to surgery or anesthesia induction
- •Requiring an intra-aortic balloon pump or ventricular assist device
- •Participation in any one of the following types of clinical studies either concurrently or within the previous 28 days: investigational blood products, pharmacologic agents or imaging materials, including dyes, investigational surgical techniques, or devices. Studies of nutrition, psychology, or socioeconomic issues are not grounds for exclusion
- •Current diagnosis of either chronic or acute renal failure (requiring dialysis) or a serum creatinine greater than or equal to 1.8 mg/dL within 30 days prior to the start of surgery
- •Current diagnosis of either chronic or acute hepatic insufficiency or a total serum bilirubin greater than or equal to 2.0 mg/dL within 30 days prior to the start of surgery
- •Pre-existing RBC antibody that may make the provision of compatible study red blood cell (RBC) components difficult
- •Patients requiring plasma removal or irradiation of the RBC
- •Patients with prior history of severe allergic transfusion reactions
- •A positive cross match to S 303 treated RBC
研究组 & 干预措施
S-303 Treated Red Blood Cells
Experimental
Patients receive S-303 treated red blood cells (RBCs).
干预措施: S-303 Red Blood Cells (RBCs) - Test (Biological)
Conventional, untreated Red Blood Cells
Active Comparator
Patients receive conventional, untreated red blood cells (RBCs).
干预措施: Conventional, untreated red blood cells (RBCs) - Control (Biological)
结局指标
主要结局
Primary Efficacy Endpoint - mean hemoglobin content
时间窗: Day 2
The mean hemoglobin content per red blood cell (RBC) component compared between the treatment groups
Primary Safety Endpoint - Adverse events
时间窗: 90 days
The frequency of adverse events (related and unrelated to study RBC components) will be compared between the treatment groups.
次要结局
- Secondary Efficacy Endpoint(Day 35)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
1 期
POOLED Red Blood Cells Prepared From Pooling 5 Leukoreduced, Irradiated RBC UnitsTransfusion ReactionAnemiaNCT03056378New York Blood Center
已完成
2 期
A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood CellsFocus: Assess Post Infusion Viability of S303 RBCsNCT01711346Cerus Corporation42
已完成
3 期
Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC TransfusionThalassemia MajorNCT01740531Cerus Corporation86
已完成
3 期
Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)InfluenzaNCT00566345Resilience Government Services, Inc.3,670
进行中（未招募）
3 期
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsAnemiaNCT03037164Cerus Corporation692